ENGLEWOOD, Colo., Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of ...

HC Wainwright reissued their buy rating on shares of Zynex (NASDAQ:ZYXI – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $17.00 target price on the ...

Zynex operates primarily in the pain management sector, with a strategic emphasis on profitable growth and sales representative productivity. The company's product portfolio includes devices for ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone ...

ENGLEWOOD, Colo. - Zynex , Inc. (NASDAQ: NASDAQ:ZYXI), a medical technology company known for noninvasive medical devices with a market capitalization of $255 million and impressive 79.7% gross ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...